newsfilter
← Latest News
GlobeNewswire·

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND filings for antibody drug conjugates (ADCs), VIP9